These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33870733)

  • 21. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Marques da Silva P; Aguiar C
    Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
    Tam K; Richards DA; Aronovitz MJ; Martin GL; Pande S; Jaffe IZ; Blanton RM
    J Card Fail; 2020 Sep; 26(9):769-775. PubMed ID: 32464187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sacubitril/valsartan protective effect on induced intestinal ischemia/reperfusion injury via immune modulation of IL6/STAT1 pathway.
    Refaie MMM; Amin EF; Hassan MN; Rifaai RA; Bayoumi AMA; Kamel MY
    J Pharm Pharmacol; 2024 Jul; 76(7):788-797. PubMed ID: 38538077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
    Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
    J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
    Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
    Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes.
    Erdogan BR; Yesilyurt-Dirican ZE; Karaomerlioglu I; Muderrisoglu AE; Sevim K; Michel MC; Arioglu-Inan E
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
    ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma renin activity as a marker for predicting the antihypertensive effect of switching to sacubitril/valsartan in treated hypertensive patients: Usefulness in daily clinical practice.
    Horio T; Iwashima Y; Yoshiyama M; Fukuda D; Rai T; Fujimoto K
    J Clin Hypertens (Greenwich); 2024 Oct; 26(10):1196-1200. PubMed ID: 39248193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
    Zhou G; Cheung AK; Liu X; Huang Y
    Clin Sci (Lond); 2014 May; 126(10):707-20. PubMed ID: 24195695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan.
    Lei B; Nakano D; Fan YY; Kitada K; Hitomi H; Kobori H; Mori H; Masaki T; Nishiyama A
    J Pharmacol Sci; 2012; 119(2):131-8. PubMed ID: 22673148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
    Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
    Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway.
    Dindaş F; Güngör H; Ekici M; Akokay P; Erhan F; Doğduş M; Yılmaz MB
    Anatol J Cardiol; 2021 Nov; 25(11):821-828. PubMed ID: 34734816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.
    Simko F; Stanko P; Repova K; Baka T; Krajcirovicova K; Aziriova S; Domenig O; Zorad S; Adamcova M; Paulis L
    Biomed Pharmacother; 2024 Apr; 173():116391. PubMed ID: 38461685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
    Li X; Braza J; Mende U; Choudhary G; Zhang P
    Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Ameliorates Endothelial Dysfunction in Diabetic C57BL/6 Mice.
    Munkhjargal U; Fukuda D; Maeda J; Hara T; Okamoto S; Bavuu O; Yamamoto T; Sata M
    J Atheroscler Thromb; 2024 Sep; 31(9):1333-1340. PubMed ID: 38616113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats.
    Alqahtani F; Mohany M; Alasmari AF; Alanazi AZ; Belali OM; Ahmed MM; Al-Rejaie SS
    Int J Med Sci; 2020; 17(18):3098-3106. PubMed ID: 33173431
    [No Abstract]   [Full Text] [Related]  

  • 40. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.